Thought leadership

• GAO extraordinary drug price increase report - a red herring?
• Mind the Gap: Assessing the different data requirements between HTA and market access bodies

• Business Development and Pricing Reimbursement: An Integrated Approach to License Evaluations

• PhRMA and the White House: Risk Sharing in the Donut Hole
• Building Value Around Regenerative Medicine

• A Broader Look at End of Life
• Exploring the Concept of
Pharmaceutical Value in BRIC Markets

• US Elections
• Exploring the Value of Pharmaceutical Investment
• Greater Value for Public Safety?

• US Presidential Elections: Who Will Be Pharma’s Man?
• UK PPRS Negotiations:
Industry Dodges OFT Value Bullet
• Reform of the NHS? Lord Darzi’s High Quality Care

• European Industry’s Pricing Policy Arguments – Is Anyone Listening?

• Bob Nordyke to Lead New Business Unit

• PriceSpective Continues Global Expansion With Payer Engagement Practice: Steve O’Malley to Lead New Business Unit

• PriceSpective Continues Global Expansion With New San Diego Office:
  Dan Ross to Lead Business Development Team

• PriceSpective Appoints Colasante as a Vice President and Murdoch as a Director

Exploring the Value of Pharmaceutical Investment

US Elections: The Impact of “Change” on Tomorrow

• European Industry’s Pricing Policy Arguments – Is Anyone Listening?

European Industry’s Pricing Policy Arguments – Is Anyone Listening?

Therapeutic Reference Pricing Hits Some Italian Regions

HTA Acts as Market Access Barrier to New Orphan Drugs

OFT’s ‘Value-based’ Proposals to Replace the UK’s PPRS Are Flawed

Countdown to Change: Implications of Medicare Part D Reform

Japan’s FTC Wants Manufacturers to Conduct Selling Price Negotiations

French Mutuelles Begin to Flex their Payer Muscles

Pfizer Appoints Sole Agency for UK Distribution

Steep Price Cuts on Off-patent Brands and More Reference Countries Feature in New Irish Pricing Agreement

New Spanish Medicines Law Contains Important P&R Changes

Are Parallel Import Savings Worthwhile? Another Report Fails to Convince

Tough Pricing Changes in Japan

Dual Pricing in Spain: Is it Legal? Don’t Hold Your Breath to Find Out

Pharma Claims Victory after California Drug Discount Ballot Stalemate, Gears up to Fight DC’s ‘Excessive Price’ Law

Turkey: New Pricing Rules Increase Attractiveness of the EU’s Latest Candidate

Factors Impacting Future Parallel Trade Growth

Mail Order To U.S.: Canada Isn’t The Only Problem

Pricing Medicines: theory and practice, challenges and opportunities

The Growing Need to Focus on France